Does the clinical course of depression determine improvement in symptoms and quality of life?

Journal of Nervous and Mental Disease

Volumn 194, Issue 4, 2006, Pages 241-248

  Moses, Tally ^a   Leuchter, Andrew F ^b,c   Cook, Ian ^b,c   Abrams, Michelle ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical course; Depression; Quality of life; Reboxetine; Remission

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; REBOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MALE; ONSET AGE; QUALITY OF LIFE; REMISSION; SINGLE BLIND PROCEDURE; STRESS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH STATUS; HUMANS; LIFE CHANGE EVENTS; MALE; MORPHOLINES; MULTIVARIATE ANALYSIS; PROBABILITY; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646462596     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nmd.0000207358.15230.80     Document Type: Article

References (63)

1. Andreoli V, Caillard V, Deo R, Rybakowski J, Versiani M (2002) Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol. 14:73-80.
2. Andrews G, Neilson M, Hunt C (1990) Diagnosis, personality and the long-term outcome of depression. Br J Psychiatry. 157:13-18.
3. Arnow BA, Constantino MJ (2003) Effectiveness of psychotherapy and combination treatment for chronic depression. J Clin Psychol. 59:893-905.
4. Bagby RM, Ryder AG, Cristi C (2002) Psychosocial and clinical predictors of response to pharmacotherapy for depression. Rev Psychiatr Neurosci. 27:250-257.
5. Bagby RM, Kennedy SH, Schuller DR (1997) Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: A retrospective analysis. J Affect Disord. 45:161-166.
6. Barge-Schaapveld D, Nicolson N, Berkhof J, deVries M (1999) Quality of life in depression: Daily life determinants and variability. Psychiatry Res. 88:173-189.
7. Bosc M (2000) Assessment of social functioning in depression. Compr Psychiatry. 41:63-69.
8. Croughan J, Secunda S, Katz M, Robins E, Mendels J, Swann A, Harris-Larkin B (1988) Sociodemographic and prior clinical course characteristics associated with treatment response ill depressed patients. J Psychiatr Res. 22:227-237.
9. Coulehan J, Schulberg H, Block M, Madonia M, Rodriguez E (1997) Treating depressed primary care patients improves their physical, mental and social functioning. Arch Intern Med. 157:1113-1120.
10. De Jonghe F, Kool S, van Aalst G, Dekker J, Peen J (2001) Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord. 64:217-229.
11. Dubini A, Bosc M, Polin V (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning. J Psychopharmacol. 11:S17-S23.
12. Ezquiaga E, García-López A, de Dios C, Leiva A, Bravo M, Montejo J (2004) Clinical and psychosocial factors associated with the outcome of unipolar major depression: A one year prospective study. J Affect Disord. 79:63-70.
13. Ezquiaga E, Garcia A, Bravo M, Pallares T (1998) Factors associated with outcome in major depression: A 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol. 33:552-557.
14. Endicott J, Nee J, Harrison W (1993) Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull. 29: 321-326.
15. Fava M, Bless E, Otto MW, Pava JA, Rosenbaum JF (1994) Dysfunctional attitudes in major depression. J Nerv Ment Dis. 182:45-49.
16. Friedman MA, Detweiler-Bedell JB, Leventhal HE, Horne R, Keitner GI, Miller IW (2004) Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clin Psychol Sci Pract. 11:47-68.
17. Gladis M, Gosch E, Dishuk N, Crits-Cristoph P (1999) Quality of life: Expanding the scope of clinical significance. J Consult Clin Psychol. 67:320-331.
18. Gold P, Goodwin F, Chrousos G (1988) Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress. N Engl J Med. 319:413-420.
19. Healy D, Healy H (1998) The clinical pharmacologic profile of reboxetine: Does it involve the putative neurobiological substrates of wellbeing? J Affect Disord. 51:313-322.
20. Hirschfeld RM, Klerman GL, Andreasen NC (1986) Psycho-social predictors of chronicity in depressed patients. Br J Psychiatry. 148:648-654.
21. Hirschfeld R, Russell J, Delgado P, Fawcett J, Friedman R, Harrison W, Koran L, Miller I, Thase M, Howland R, Connolly M, Miceli R (1998) Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry. 59:669-675.
22. Hirschfeld R, Dunner D, Keitner G, Klein D, Koran L, Kornstein S, Markowitz J, Miller I, Nemeroff C, Ninan P, Rush A, Schatzberg A, Thase M, Trivedi M, Borian F, Crits-Christoph P, Keller M (2002) Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy and their combination. Biol Psychiatry. 51:123-133.
23. Hoencamp E, Haffmans P, Duivenvoorden H, Knegtering H, Dijken W (1994) Predictors of (non)-response in depressed outpatients treated with a three-phase sequential medication strategy. J Affect Disord. 31:235-246.
24. Joyce P, Mulder R, Cloninger C (1994) Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord. 30:35-46.
25. Joyce P, Mulder R, Luty S, Sullivan P, McKenzie J, Abbott R, Stevens I (2002) Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 36:384-391.
26. Judd L, Akiskal H, Zeller P, Paulus M, Leon A, Maser J, Endicott J, Coryell W, Kunovac J, Mueller T, Rice J, Keller M (2000) Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 57:375-380.
27. Katz M, Halbreich U, Bowden C, Frazer A, Pinder R, Rush A, Wheatley D, Lebowitz B (2002) Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. Neuropsychopharmacology. 27:319-328.
28. Keitner G, Ryan C, Miller I, Norman W (1992) Recovery from major depression: Factors associated with twelve-month outcome Am J Psychiatry. 149:93-98.
29. Keller M (2004) Remission versus response: The new gold standard of antidepressant care. J Clin Psychiatry. 65:53-59.
30. Keller M (2001) Role of serotonin and noradrenaline in social dysfunction: A review of data on reboxetine and the Social Adaption Self-evaluation Scale (SASS). Gen Hosp Psychiatry. 23:15-19.
31. Kennedy S, Eisfeld B, Meyer J, Bagby R (2001) Antidepressants in clinical practice: Limitations of assessment methods and drug response. Hum Psychopharmacol Clin Exp. 16:105-114.
32. Klein D, Schatzberg A, McCullough J, Dowling F, Goodman D, Howland R, Markowitz J, Smith C, Thase M, Rush A, LaVange L, Harrison W, Keller M (1999) Age of onset in chronic major depression: Relation to demographic and clinical variables, family history and treatment response. J Affect Disord. 55:149-157.
33. Kocsis J, Zisook S, Davidson J, Shelton R, et al. (1997) Double-blind comparison of sertraline, imipramine and placebo in the treatment of dysthymia: Psychosocial outcomes. Am J Psychiatry. 154:390-395.
34. Kocsis J, Schatzberg A, Rush A, Klein D, Howland R, Gniwesch L, Davis S, Harrison W (2002) Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry. 59:723-728.
35. Kupfer D, Spiker D (1981) Refractory depression: Prediction of non-response by clinical indicators. J Clin Psychiatry. 42:307-312.
36. Lloyd C, Zissok S, Click M, Jaffe K (1981) Life events and response to antidepressants. J Hum Stress. 7:2-15.
37. Markowitz J, Friedman R, Miller N, Spielman L, Moran M, Kocsis J (1996) Interpersonal improvement in chronically depressed patients treated with desipramine. J Affect Disord. 41:59-62.
38. Mazure C, Bruce M, Maciejewski P, Jacobs SC (2000) Adverse life events and cognitive personality characteristics and the prediction of major depression and antidepressant response. Am J Psychiatry. 157:896-903.
39. Mertler C, Vannatta R (2002) Advanced and Multivariate Statistical Methods (2nd ed). Los Angeles: Pyrczak Publishing.
40. Miller I, Keitner G, Schatzberg A, Klein D, Thase M, Rush A, Markowitz J, Schlager D, Kornstein S, Davis S, Harrison W, Keller M (1998) The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 59:608-619.
41. Mintz J, Mintz L, Arruda M, Hwang S (1992) Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 49:761-768.
42. Monroe S, Kupfer D, Frank E (1992) Life stress and treatment course of recurrent depression. J Consult Clin Psychol. 60:718-724.
43. Morishita S, Arita S (2003) Possible predictors of response to fluvoxamine for depression. Hum Psychopharmacol Clin Exp. 18:197-200.
44. Nierenberg A (2003) Predictors of response to antidepressants: General principles and clinical implications. Psychiatr Clin North Am. 26:345-352.
45. O'Leary D, Costello F, Gormley N, Webb M (2000) Remission onset and relapse in depression an 18-month prospective study of course for 100 first admission patients. J Affect Disord. 57:159-171.
46. Papakostas G. Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M (2004) Quality of life assessments in major depressive disorder: A review of the literature. Gen Hosp Psychiatry. 26:13-17.
47. Parker G, Tennant C, Blignault I (1985) Predicting improvement in patients with nonendogenous depression. Br J Psychiatry. 146:287-293.
48. Parker G, Hadzi-Pavlovic D, Brodaty H, Boyce P, et al. (1992) Predicting the course of melancholic and nonmelancholic depression: A naturalistic comparison study. J Nerv Ment Dis. 180:693-702.
49. Paykel E, Ramana R, Cooper Z, Hayhurst H; Barocka A (1995) Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 25:1171-1180.
50. Paykel ES (2001) The evolution of life events research in psychiatry. J Affect Disord. 62:141-149.
51. Ramana R, Paykel E, Cooper Z, Hayhurst H, Surtees P (1995) Remission and relapse in major depression: A two-year prospective follow-up study. Psychol Med. 25:1161-1170.
52. Rafanelli C, Park S, Ruini C, Ottolini F, Cazzaro M, Fava G (2000) Rating well-being and distress. Stress Med. 16:55-61.
53. Reno R, Halaris A (1990) The relationship between life stress and depression in an endogenous sample. Compr Psychiatry. 31:25-33.
54. Scott J, Eccleston D, Boys R (1992) Can we predict the persistance of depression? Br J Psychiatry. 161:633-637.
55. Scott J (1994) Predictors of non-response to antidepressants. In WA Nolen, J Zohar (Eds), Refractory Depression: Current Strategies and Future Directions (pp 19-28). Oxford, UK: John Wiley & Sons.
56. Thase ME (2003) Evaluating antidepressant therapies: Remission as the optimal outcome. J Clin Psychiatry. 64:18-25.
57. Tomaszewska W, Peselow E, Barouche F, Fieve R (1996) Antecedent life events, social supports and response to antidepressants in depressed patients. Acta Psychiatr Scand. 94:352-357.
58. Tranter R, Healy H, Cattell D (2002) Functional effects of agents differentially selective to noradrenergic or serotonergic systems. Psychol Med. 32:517-524.
59. Vallejo J, Gasto C, Catalan R, Bulbena A, Menchon J (1991) Predictors of antidepressant treatment outcome in melancholia: Psychosocial, clinical and biological indicators. J Affect Disord. 21:151-162.
60. Vittengl JR, Clark LA, Jarrett RB (2004) Improvement in social-interpersonal functioning after cognitive therapy for recurrent depression. Psychol Med. 34:643-658.
61. Wells K, Burnam M, Rogers W, Hays R, Camp P (1992) The course of depression in adult outpatients: results from the medical outcomes study. Arch Gen Psychiatry. 49:788-794.
62. World Health Organization (2001) The World Health Report 2001 - Mental Health: New Understanding, New Hope. Available at: http://www.who.int/whr/2001/ en/.
63. Zimmerman M, Pfohl B, Coryell W, Stangl D (1987) The prognostic validity of DSM-III Axis IV in depressed inpatients. Am J Psychiatry. 144:102-106.